In DepthScience Policy

FDA enforcement actions plummet under Trump

See allHide authors and affiliations

Science  05 Jul 2019:
Vol. 365, Issue 6448, pp. 12-13
DOI: 10.1126/science.365.6448.12

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

From monitoring clinical trials and approving new medicines and vaccines, to ensuring the safety of blood transfusions, medical devices, groceries, and more, the U.S. Food and Drug Administration (FDA) is one of the nation's most vital watchdogs. By several key measures, however, FDA's compliance and enforcement actions have plummeted since President Donald Trump took office, a Science investigation has found. The Silver Spring, Maryland–based agency's "warning letters"—a primary tool for keeping dangerous or ineffective drugs and devices and tainted foods off the market—have fallen by one-third, for example. FDA watchers say they can't pinpoint what's driving the decline, but they are alarmed.

  • * This story has been supported by the Science Fund for Investigative Reporting.

View Full Text